London · Delayed Price · Currency is GBP · Price in GBX Diaceutics Earnings Call Transcripts
Fiscal Year 2024
-
2024 marked a breakout year with 39% revenue growth, strong recurring revenue, and major U.S. expansion. The business is shifting to profitability in 2025, driven by new enterprise contracts, PMx solution launches, and robust order book visibility. Growth is underpinned by high margins, a leading pharma client base, and continued investment in AI and data.
-
Delivered strong H1 2024 growth with revenue up 24% and gross margin at 87%, driven by the launch of PMX and expansion in rare disease and Europe. PMX is expected to significantly boost revenue per brand, and the business is on track for profitability and cash flow in 2025.
-
Transitioning to a high-margin, recurring revenue model, the business leverages a proprietary global lab network and AI-driven DXRX platform to deliver daily insights for pharma clients. Strategic partnerships, expanded operations, and a robust roadmap position it for growth in oncology and non-oncology markets.